WinSanTor
- Biotech or pharma, therapeutic R&D
WinSanTor, Inc. (WST) is on the brink of a major breakthrough in the treatment of peripheral neuropathy, a devastating condition affecting hundreds of millions of people worldwide. In its final Phase 3 trial, WinSanTor is developing what could be the first disease-modifying treatment for peripheral neuropathy. Unlike pain management drugs that only address symptoms, our regenerative approach aims to heal and reverse nerve damage, offering hope where none previously existed. PLEASE, NO MEETING REQUESTS FROM CROs, CMOs, SERVICE PROVIDERS OR ADVISERS
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}